Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04718233
Other study ID # sildenafilcitrate89
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 5, 2018
Est. completion date July 1, 2019

Study information

Verified date January 2021
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with recurrent pregnancy loss are known to have decreased uterine artery blood flow. Nitric oxide plays a major role in increasing uterine blood flow during the luteal phase. This study is done to evaluate the effects of sildenafil on blood flow indices in the patients with recurrent pregnancy loss due to impaired uterine artery blood flow.


Description:

Study Setting: The study will be conducted in recurrent pregnancy loss outpatient clinic at Ain shams university maternity hospital. Study Population: Patients with unexplained recurrent miscarriage attending Ain shams university maternity hospital's outpatient clinic. This study will be conducted on 80 women distributed into 2 groups each is 40 women in fertile age with history of two or more recurrent spontaneous abortions and decreased uterine artery blood flow(PI>2.02(Mansour et al., 2018). First group will be placebo controlled and the second group will be given sildenafil citrate. Women will be asked to attend during the 21-23 day of the cycle and will be subjected to: History taking and Full clinical examination. Clinical examination will be done including general, abdominal and pelvic examination. General examination: including general appearance, weight, height and vital signs Abdominal examination: to assure freedom of any organic clinically detectable pathologic lesions. Pelvic examination: included inspection of the external genitalia, speculum examination of the vagina to rule out infection, and bimanual assessment of uterine size and position as well as exclusion of adnexal masses. Laboratory investigations: Routine investigations including: CBC, fasting and postprandial blood sugar, urine analysis, kidney function and liver function will be done. The endocrine evaluation consisted in measuring thyroid-stimulating hormone, free thyroxin, and progesterone levels on day 21 of the menstrual cycle. Sonography: Sonography will be performed using Samsung H60 with convex probe (multi-frequency AD 2~ 8 MHz) to perform trans-vaginal examination. Examination will be performed in the second phase of the menstrual cycle, at mid-luteal day. Pulsed wave Doppler will be used to obtain clear, consistent, flow velocity wave forms of both uterine arteries. Pulsatility index (PI) will be measured bilaterally. The PI reported will be the arithmetic mean for the last three cardiac cycles. (Goswamy and Steptoe, 1988) classification will be used to determine the wave types. According to this classification, the FVW of the circumflex artery can be of 3 types : Type A when the diastolic component is present but not continuous with the systole, and ends before the next cardiac cycle. Type B when a diastole is present and continues with the systole, but ends before the next cardiac cycle. Type C when a diastole is present and continues with the systole and into the next cardiac cycle. The majority of research has centered on an elevation in the RI or PI to detect the presence of increased uterine artery blood flow resistance in non- pregnant states. Criteria for an abnormal uterine artery Pulsatility index (PI) cutoff (PI> 2.02) and abnormal sub-endometrial blood flow Resistant Index (RI) (RI>0.6) (Mansour et al., 2018). Steps and methods: The participants will be two groups of 80 patients with history of recurrent pregnancy loss, each is 40. All patients will be scanned transvaginally with transvaginal Doppler sonography 6 to 8 days after ovulation to measure the pulsatility index (PI), resistance index (RI) and systolic to diastolic ratio (S/D) of the right and left main uterine arteries and sub-endometrial blood flow resistance index (RI). Sildenafil citrate at a dose of 25mg or placebo will be administered orally in patients with recurrent pregnancy loss and the blood flow indices will be measured after 3 hours. The student test will be used for analysis of the results, P< 0.05 will be considered significant. With 95% confidence interval. P values ≥5% considered to be significant.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date July 1, 2019
Est. primary completion date July 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: 1. History of 2 or more unexplained recurrent miscarriage. 2. Child bearing period (18-35 years old). 3. Non pregnant state. 4. Regular menstrual cycles for the previous three months before the study. 5. No hormonal contraception or intrauterine device. 6. impaired uterine artery blood flow (PI >2.02) (Mansour et al., 2018). Exclusion Criteria: - 1-Having any possible causes of abortion: anatomical, genetic, endocrinological, infectious, or immunological. 2- Autoimmune disorders which may affect blood vessels and their blood flow (systemic lupus). 3- Systemic disease that might affect the hemodynamic indices (e.g. thrombocytopenia, thyrotoxicosis … etc.). 4- Diagnosed or treated thrombophilia. 5- Any vascular disease (e.g. coronary artery disease). 6- History of oophorectomy. 7- History of consanguinity. 8- Family history of chromosomal abnormalities (e.g. trisomy 21, trisomy 13… etc.).

Study Design


Intervention

Drug:
Sildenafil 25Mg Tablet
Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
Placebo Oral Tablet
placebo will be administered orally in patients with recurrent pregnancy loss

Locations

Country Name City State
Egypt Ain shams university maternity hospital Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary uterine artery blood flow indices uterine artery PI, RI 3 hours
See also
  Status Clinical Trial Phase
Recruiting NCT01946945 - Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis Phase 2
Completed NCT02572154 - Sperm DNA Fragmentation in Recurrent Pregnancy Loss N/A
Completed NCT03174951 - Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Phase 2
Recruiting NCT05444283 - Genomic Predictors of Recurrent Pregnancy Loss
Active, not recruiting NCT04621773 - Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
Recruiting NCT02990403 - The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss Phase 4
Recruiting NCT02990390 - The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla N/A
Not yet recruiting NCT05612620 - Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05520112 - Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells Phase 1/Phase 2
Suspended NCT04397042 - SCUBE-1 and Carotid Intima Media Thickness in Recurrent Pregnancy Loss
Not yet recruiting NCT05341856 - Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL Early Phase 1
Recruiting NCT06007560 - Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss N/A
Completed NCT02386384 - TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure N/A
Recruiting NCT01635426 - Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages Phase 2/Phase 3
Suspended NCT01546350 - Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH Phase 2
Completed NCT00721591 - Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy N/A
Terminated NCT00564174 - Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT N/A
Completed NCT04455256 - Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05237843 - Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss Phase 1
Recruiting NCT02144064 - Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin Phase 3